Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.48 |
| ▸ | GRM5 | P41594 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022147 | 0.82 | METAP1 (0.51) | KDM4ETDP1FFAR1GRM5L3MBTL1 | |
| SCHEMBL2836445 | 0.81 | ACLY (0.39) | FFAR1 | |
| SCHEMBL27930092 | 0.80 | KDM4E (0.54) | KDM4ETDP1FFAR1GRM5L3MBTL1 | |
| SCHEMBL4017715 | 0.79 | GRM5 (0.40) | KDM4EGRM5NPC1RAB9A | |
| SCHEMBL28509029 | 0.72 | KDM4E (0.45) | KDM4ETDP1FFAR1GRM5L3MBTL1 | |
| SCHEMBL12320145 | 0.72 | KDM4E (0.47) | KDM4ETDP1FFAR1GRM5L3MBTL1 | |
| SCHEMBL20665659 | 0.72 | KDM4E (0.63) | KDM4ETDP1FFAR1GRM5L3MBTL1 | |
| SCHEMBL31420202 | 0.71 | CCR1 (0.44) | KDM4ETDP1FFAR1GRM5L3MBTL1 | |
| SCHEMBL1443106 | 0.71 | KDM4E (0.68) | KDM4ETDP1GRM5L3MBTL1ALOX15 | |
| SCHEMBL20665699 | 0.71 | RAB9A (0.44) | KDM4ETDP1FFAR1GRM5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| EP-1504001-B1 | 2-(2-PYRIDYL)-5-PHENYL-6-AMINOPYRIMIDINE, METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION AND USE THEREOF FOR COMBATING NOXIOUS FUNGI | BASF SE (DE) | 2009-04-15 | — | — | EP | disclosed |
| US-7320975-B2 | 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20050107401-A1 | 2- (2-pyridyl) -5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-19 | — | — | US | disclosed |
| EP-1504001-A1 | 2-(2-PYRIDYL)-5-PHENYL-6-AMINOPYRIMIDINE, METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION AND USE THEREOF FOR COMBATING NOXIOUS FUNGI | BASF Aktiengesellschaft (DE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003070721-A1 | 2-(2-PYRIDYL)-5-PHENYL-6-AMINOPYRIMIDINE, METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION AND USE THEREOF FOR COMBATING NOXIOUS FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | KDM4E 2439/4885TDP1 34/4885FFAR1 4671/4885 |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, SYNJ1, PARK7 | KDM4E 3159/4885TDP1 62/4885FFAR1 4575/4885 |
| US-20050107401-A1 | 2- (2-pyridyl) -5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi | HAAO, HAO1, DAO | KDM4E 2544/4885TDP1 377/4885FFAR1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.